A Phase III/IV Factorial Randomized Double-blind Trial to Compare the Addition of Dapagliflozin vs Placebo and Rosuvastatin/Ezetimibe Versus Pitavastatin in Patients With HIV on Integrase Strand Transfer Inhibitor-based Antiretrovirals With Elevated Metabolic Risk

People with HIV are at a higher risk of cardiovascular diseases (CVD) due to the effects of the virus and its treatment. Integrase strand transfer inhibitors (INSTIs), a common HIV treatment, are associated with increased CVD risk and metabolic issues, such as weight gain and high blood pressure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, however, have been working well in reducing CVD events and hospitalizations due to heart failure, irrespective of diabetes presence. They also help in reducing weight and blood pressure. Pitavastatin has shown to work in lowering CVD events in people with HIV, but its availability is limited. This benefit is thought to be common to all statins, but this has not yet been confirmed. This study will examine the impact of dapagliflozin vs. placebo on metabolic parameters in people with HIV with high metabolic risk who are on INSTI-based ART.

开始日期2024-08-01

申办/合作机构

Kirby Institute

NCT06262685 / Not yet recruiting临床4期

A Multicenter, Controlled, Randomized, Single-blind Phase IV Trial Assesses Efficacy, Safety, and Cost of Pre-emptive Genotyping in a Cardiovascular Risk Population Eligible for High/Moderate-intensity Statins

This is a Phase IV multicentre adaptive single-blinded randomized clinical trial if preemptively genotyping populations at risk of cardiovascular disease susceptible of receiving high or moderate doses of statin therapy is efficacious, cost-efficacious, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol

开始日期2024-03-04

申办/合作机构

Hospital Universitario La Paz

[+1]

KCT0007827 / Recruiting临床1期

A open-label, multiple-dose, two-arm, one-sequence, crossover study to investigate the pharmacokinetic drug interaction between Pitavastatin and Ezetimibe after oral administration in healthy volunteers

开始日期2022-10-29

申办/合作机构

Kuhnil Pharma Co., Ltd.

100 项与匹伐他汀镁相关的临床结果

登录后查看更多信息

100 项与匹伐他汀镁相关的转化医学

登录后查看更多信息

100 项与匹伐他汀镁相关的专利（医药）

登录后查看更多信息

1,048

项与匹伐他汀镁相关的文献（医药）

2024-04-01·Journal of applied toxicology : JAT

Pitavastatin induces caspase‐mediated apoptotic death through oxidative stress and DNA damage in combined with cisplatin in human cervical cancer cell line

Article

作者: Eken, Ayşe ; Bucurgat, Ülkü Ündeğer ; Hacıseyitoğlu, Aysun Ökçesiz ; Doğan, Tuğbagül Çal ; Dilsiz, Sevtap Aydın ; Canpınar, Hande

Abstract:

Pitavastatin (PITA) is a 3‐hydroxy‐3‐methylglutaryl‐CoA (HMG‐CoA) reductase inhibitor to treat hypercholesterolemia and in recent studies is focused that its potential anti‐cancer effect. This study was aimed to elucidate the effect of PITA alone and in combination with cisplatin on cervical cancer cells (HeLa) in vitro. Cytotoxicity of PITA (5–200 μM) was evaluated by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) and neutral red uptake (NRU) assays for 24, 48, and 72 h. Cell apoptosis and cell cycle analyses were performed in flow cytometry (0.1–100 μM). The evaluation of genotoxic effects and oxidative DNA damage of PITA (2–200 μM) were performed with standard comet assay, formamidopyrimidine glycosylase (fpg)‐modified comet assay, and reactive oxygen species (ROS) activation in HeLa cells. PITA alone reduced cell viability in a dose‐dependent manner (20–200, 20–200, and 5–200 μM for 24, 48, and 72 h, respectively, in MTT). The combined treatment of PITA with cisplatin resulted in significantly greater inhibition of cell viability. ROS and DNA damage increased significantly at 100 μM for 4 h and 20 μM for 24 h, respectively. PITA‐induced apoptosis, an increased proportion of sub G1 cells, was monitored, and also, it increased the expression of active caspase‐9 and caspase‐3 and upregulated cleaved poly adenosine diphosphate ribose polymerase (PARP) by western blotting and caspase 3/8/9 multiple assay kit. We conclude that PITA can be used to efficiently cervical cancer studies, and promising findings have been obtained for further studies.

2024-03-01·Clinical pharmacology and therapeutics

Successful Prediction of Human Hepatic Concentrations of Transported Drugs Using the Proteomics‐Informed Relative Expression Factor Approach

Article

作者: Tournier, Nicolas ; Marie, Solène ; Gáborik, Zsuzsanna ; Unadkat, Jashvant D ; Yin, Mengyue ; Balhara, Ankit

Tissue drug concentrations determine the efficacy and toxicity of drugs. When a drug is the substrate of transporters that are present at the blood:tissue barrier, the steady‐state unbound tissue drug concentrations cannot be predicted from their corresponding plasma concentrations. To accurately predict transporter‐modulated tissue drug concentrations, all clearances (CLs) mediating the drug's entry and exit (including metabolism) from the tissue must be accurately predicted. Because primary cells of most tissues are not available, we have proposed an alternative approach to predict such CLs, that is the use of transporter‐expressing cells/vesicles (TECs/TEVs) and relative expression factor (REF). The REF represents the abundance of the relevant transporters in the tissue vs. in the TECs/TEVs. Here, we determined the transporter‐based intrinsic CL of glyburide (GLB) and pitavastatin (PTV) in OATP1B1, OATP1B3, OATP2B1, and NTCP‐expressing cells and MRP3‐, BCRP‐, P‐gp‐, and MRP2‐expressing vesicles and scaled these CLs to in vivo using REF. These predictions fell within a priori set twofold range of the hepatobiliary CLs of GLB and PTV, estimated from their hepatic positron emission tomography imaging data: 272.3 and 607.8 mL/min for in vivo hepatic sinusoidal uptake CL, 47.8 and 17.4 mL/min for sinusoidal efflux CL, and 0 and 4.20 mL/min for biliary efflux CL, respectively. Moreover, their predicted hepatic concentrations (area under the hepatic concentration‐time curve (AUC) and maximum plasma concentration (Cmax)), fell within twofold of their mean observed data. These data, together with our previous findings, confirm that the REF approach can successfully predict transporter‐based drug CLs and tissue concentrations to enhance success in drug development.

2024-02-01·Current medicinal chemistry

Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis

Article

作者: Lou, Dandi ; Zhang, Xingfen ; Zheng, Dingcheng ; Ma, Xueqiang ; Wu, Feng ; Fu, Rongrong

Background::

Previous studies have found a potential role for statins in liver cancer prevention.

Objective::

This study aimed to explore the effect of different types of statins on the incidence of liver cancer.

Methods::

Relevant articles were systematically retrieved from PubMed, EBSCO, Web of Science, and Cochrane Library databases from inception until July 2022 to explore the relationship between lipophilic statins or hydrophilic statins exposure and the incidence of liver cancer. The main outcome was the incidence of liver cancer.

Results::

Eleven articles were included in this meta-analysis. The pooled results showed a reduced incidence of liver cancer in patients exposed to lipophilic statins (OR=0.54, p < 0.001) and hydrophilic statins (OR=0.56, p < 0.001) compared with the non-exposed cohort. Subgroup analysis showed that both exposures to lipophilic (Eastern countries: OR=0.51, p < 0.001; Western countries: OR=0.59, p < 0.001) and hydrophilic (Eastern countries: OR=0.51, p < 0.001; Western countries: OR=0.66, p=0.019) statins reduced the incidence of liver cancer in Eastern and Western countries, and the reduction was most significant in Eastern countries. Moreover, atorvastatin (OR=0.55, p < 0.001), simvastatin (OR=0.59, p < 0.001), lovastatin (OR=0.51, p < 0.001), pitavastatin (OR=0.36, p=0.008) and rosuvastatin (OR=0.60, p=0.027) could effectively reduce the incidence of liver cancer, unlike fluvastatin, cerivastatin and pravastatin.

Conclusion::

Both lipophilic and hydrophilic statins contribute to the prevention of liver cancer. Moreover, the efficacy was influenced by the region and the specific type of statins used.

项与匹伐他汀镁相关的新闻（医药）

2024-05-30

·Science Daily

Statin therapy may prevent cancer by blocking inflammatory protein

Scientists have found that statins -- commonly used cholesterol-lowering drugs -- may block a pathway that leads to the development of cancer in the context of chronic inflammation. A new study led by investigators from Mass General Cancer Center, a founding member of the Mass General Brigham healthcare system, reveals that statins -- commonly used cholesterol-lowering drugs -- may block a particular pathway involved in the development of cancer that results from chronic inflammation. The findings are published in Nature Communications. "Chronic inflammation is a major cause of cancer worldwide," said senior author Shawn Demehri, MD, PhD, a principal investigator at the Center for Cancer Immunology and Cutaneous Biology Research Center of Massachusetts General Hospital and an associate professor of Dermatology at Harvard Medical School. "We investigated the mechanism by which environmental toxins drive the initiation of cancer-prone chronic inflammation in the skin and pancreas," says Demehri, who is also theBob and Rita Davis Family MGH Research Scholar 2023-2028. "Furthermore, we examined safe and effective therapies to block this pathway in order to suppress chronic inflammation and its cancer aftermath." Demehri and his colleagues' study relied on cell lines, animal models, human tissue samples and epidemiological data. The group's cell-based experiments demonstrated that environmental toxins (such as exposure to allergens and chemical irritants) activate two connected signaling pathways called the TLR3/4 and TBK1-IRF3 pathways. This activation leads to the production of the interleukin-33 (IL-33) protein, which stimulates inflammation in the skin and pancreas that can contribute to the development of cancer. When they screened a library of U.S. Food and Drug Administration-approved drugs, the researchers found that a statin, pitavastatin, effectively suppresses IL-33 expression by blocking the activation of the TBK1-IRF3 signaling pathway. In mice, pitavastatin suppressed environmentally-induced inflammation in the skin and the pancreas and prevented the development of inflammation-related pancreatic cancers. In human pancreas tissue samples, IL-33 was over-expressed in samples from patients with chronic pancreatitis (inflammation) and pancreatic cancer compared with normal pancreatic tissue. Also, in analyses of electronic health records data on more than 200 million people across North America and Europe, use of pitavastatin was linked to a significantly reduced risk of chronic pancreatitis and pancreatic cancer. The findings demonstrate that blocking IL-33 production with pitavastatin may be a safe and effective preventive strategy to suppress chronic inflammation and the subsequent development of certain cancers. "Next, we aim to further examine the impact of statins in preventing cancer development in chronic inflammation in liver and gastrointestinal tract and to identify other novel, therapeutic approaches to suppress cancer-prone chronic inflammation" said Demehri.

2024-05-21

·药通社

己酮可可碱注射液、盐酸格拉司琼片过评！3款创新药获批上市，520、521批件送达！

万人展会！一次性看现行法规下如何办理B证、MAH立项思路及案例、吸入制剂研发思路等……520批件送达信息昨天的批次共有10个受理号获批，2个品种过评。过评品种为山东北大高科华泰制药有限公司的2品规注射用奥美拉唑，鲁南贝特制药有限公司的阿昔莫司胶囊。葡萄糖注射液广东大冢制药和江西科伦的葡萄糖注射液是用非一致性评价来申报的。本身也可以免除一致性评价，临床应用价值已经得到了广泛认可，且它们的质量标准相对成熟和稳定，因此不需要再进行一致性评价来证明其质量和疗效。此外，葡萄糖注射液作为基础输液，其生产工艺和质量控制相对简单，且已有较为完善的质量标准和规范，因此不需要通过一致性评价来进一步证明其安全性和有效性。同时，这也有助于减轻企业的负担，加快药品的上市进程，更好地满足临床需求。这次江西科伦新增了一个批件。图源 | 药融云数据库根据药融云数据库，葡萄糖注射液在全国医院（全终端）的销售量近年来都维持得相对稳定。注射用奥美拉唑本次过评的还有山东北大高科华泰制药有限公司的2品规注射用奥美拉唑。目前注射用奥美拉唑已有51家过评。如下几家中了第七批集采：浙江亚太药业股份有限公司武汉天安医药科技有限公司哈尔滨三联药业股份有限公司华北制药河北华诺有限公司海南全星制药有限公司湖南恒生制药股份有限公司宜昌人福药业有限责任公司陕西博森生物制药股份集团有限公司湖南赛隆药业有限公司湖南科伦制药有限公司阿昔莫司胶囊RECRUIT提到降血脂，很多人首先想到的就是他汀类药物，常见的有瑞舒伐他汀、阿托伐他汀、匹伐他汀、辛伐他汀等等。这是因为他汀在调脂市场独占鳌头，市场份额达到了80%以上，处于无可撼动的地位。阿昔莫司胶囊是一种用于降低甘油三酯水平的药物，适用于那些对其他治疗（如他汀类药物或贝特类药物）反应不充分的患者。阿昔莫司批得很少，有效批文只有这几家，都是2001年首次获批的老批文了：地奥集团成都药业股份有限公司鲁南贝特制药有限公司四川豪运药业股份有限公司根据药融云数据库，近年来阿昔莫司胶囊销量有所下降。图源 | 药融云数据库CMC议程已出！B证、CRO产品立无可立？会议邀请到了数十位企业决策层破解立项难题↓扫码查看所有议程521批件送达信息5月21日共有66个批准文件送达，共有两个过评品种，分别是广州万正药业有限公司的己酮可可碱注射液和福安药业集团宁波天衡制药有限公司的盐酸格拉司琼片。己酮可可碱注射液过评达到了8家，目前仅进入地方集采。图源 | 药融云数据库盐酸格拉司琼片目前市场上有4个有效批文，仅过评1家。图源 | 药融云数据库图源 | 药融云数据库新药板块，上海倍而达药业的甲磺酸瑞奇替尼胶囊、海思科的苯磺酸颗粒加巴林胶囊、信立泰的阿利沙坦酯氨氯地平片、江苏恒瑞的氟唑帕利胶囊批件送达。甲磺酸瑞奇替尼胶囊适应症: 适用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的治疗。重要信息: 甲磺酸瑞奇替尼胶囊（BPI-7711）是一种1类创新药物，属于第三代EGFR-TKI，对EGFR T790M突变具有显著的抑制活性。苯磺酸颗粒加巴林胶囊适应症: 用于治疗成人糖尿病性周围神经病理性疼痛。重要信息: 苯磺酸克利加巴林胶囊是一种1类创新药物，是抑制性神经递质γ-氨基丁酸（GABA）的结构衍生物。阿利沙坦酯氨氯地平片药物类型: AT1R拮抗剂、L-type calcium channel阻滞剂重要信息: 阿利沙坦酯是中国制药企业信立泰研发的一种降压药，属于沙坦类药物，通过选择性的与血管紧张素Ⅱ受体结合，阻断血管紧张素Ⅱ引起的血管收缩，促进醛固酮分泌，达到降低血压的目的。阿利沙坦酯与苯磺酸氨氯地平的组合药物，用于治疗高血压。氟唑帕利胶囊氟唑帕利是一种聚腺苷二磷酸核糖聚合酶（PARP）抑制剂，可特异性杀伤BRCA突变的肿瘤细胞。2020年12月14日，国家药监局官网发布信息显示，恒瑞医药1类创新药氟唑帕利胶囊（商品名：艾瑞颐）上市。氟唑帕利为小分子PARP抑制剂，可抑制BRCA1/2功能异常细胞中的DNA修复过程，诱导细胞周期阻滞，进而抑制肿瘤细胞增殖。该品种上市为患者提供了新的治疗选择。2024年4月2日，恒瑞医药发布公告，氟唑帕利胶囊、甲磺酸阿帕替尼片被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为氟唑帕利单药或联合阿帕替尼治疗gBRCA突变的HER2阴性乳腺癌。根据受理号，这次是申报氟唑帕利单药或联合甲磺酸阿帕替尼用于伴有胚系BRCA 突变（gBRCAm）的 HER2 阴性乳腺癌患者的治疗。图源 | 药融云数据库全目录：2024年05月21日药品批准证明文件送达信息2024年05月21日药品批准证明文件送达信息-1CMC议程已出！B证、CRO产品立无可立？会议邀请到了数十位企业决策层破解立项难题↓扫码查看所有议程推荐阅读

一致性评价上市批准

2024-04-23

·BioSpace

Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency

WINNIPEG, MB / ACCESSWIRE / April 23, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that through its subsidiary, Medicure International Inc., the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MC-1, an investigational product for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency. Fast Track designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. The designation was requested based on the potential for MC-1 to address an unmet medical need for PNPO deficiency, a serious and life-threatening condition. Medicure is in the launch phase of its Phase 3 clinical trial to treat approximately 10 PNPO deficient patients at sites in the U.S. and Australia with daily doses of MC-1. PNPO deficiency is a rare neurometabolic disorder, often leading to neonatal onset seizures that are resistant to other antiseizure medications, resulting in severe neurological dysfunction and ultimately death if untreated. The FDA has granted both a Rare Pediatric Disease Designation and an Orphan Drug Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted an Orphan Drug Designation to MC-1 for the treatment of PNPO deficiency. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, Medicure is eligible to receive a priority review voucher from the FDA, which can be redeemed or sold, and provides significant value. About Medicure Inc. Medicure is a pharmaceutical company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit . To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com. For more information on Medicure please visit . For additional information about AGGRASTAT®, please visit or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit or refer to the full Prescribing Information. To be added to Medicure's e-mail list, please visit: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F. AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks. For more information, please contact: Dr. Albert D. Friesen Chief Executive Officer Tel. 888-435-2220 Fax 204-488-9823 E-mail: info@medicure.com SOURCE: Medicure, Inc. View the original press release on accesswire.com

临床3期快速通道孤儿药申请上市优先审批

100 项与匹伐他汀镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11092	匹伐他汀镁	C10AA08	DB08860

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
血脂障碍	美国	Medicure, Inc.	2017-07-14
高脂血症	美国	Medicure, Inc.	2017-07-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01710007 (CTgov)	临床3期	高胆固醇血症	202	Lipitor (Lipitor)	鑰醖襯窪鑰廠淵淵壓憲(願網淵醖構醖艱顧範製) = 襯鏇範構鏇願膚糧憲艱夢網鏇窪襯蓋製觸膚範 (築觸窪齋醖醖積襯選築, 壓鑰顧夢蓋襯築齋齋簾 ~ 構夢製餘遞簾鏇觸範齋) 更多	-	2023-07-17
				1PC002 (1PC002)	鑰醖襯窪鑰廠淵淵壓憲(願網淵醖構醖艱顧範製) = 網範構衊淵壓膚壓構淵夢網鏇窪襯蓋製觸膚範 (築觸窪齋醖醖積襯選築, 鹹鹹壓積構鹽願鹽鹽鑰 ~ 鬱衊醖獵糧範鬱夢鏇製) 更多
ESC2021	N/A	-	-	Pitavastatin	膚衊網淵選範齋選選築(顧鏇襯願鹽觸衊獵簾顧) = 夢廠膚鬱糧廠選蓋願廠簾顧醖觸製選網選壓壓 (鬱構衊觸遞鹹衊壓築獵 ) 更多	-	2021-08-27
				Moderate-intensity statin (MIS)	膚衊網淵選範齋選選築(顧鏇襯願鹽觸衊獵簾顧) = 壓製淵餘鏇鏇鑰齋夢窪簾顧醖觸製選網選壓壓 (鬱構衊觸遞鹹衊壓築獵 ) 更多
NCT01871792 (PRINCIPLE-II, Pubmed \| J Clin Med)	临床4期	肾功能不全	70	Pitavastatin 4 mg/day	淵構遞顧獵鹽艱範襯夢(遞齋積製範構積醖獵蓋) = 鹽構醖簾顧鏇膚繭遞簾築淵構糧鬱衊醖範積鬱 (遞艱憲構鏇夢餘膚顧餘 ) 更多	积极	2020-11-17
				Placebo	淵構遞顧獵鹽艱範襯夢(遞齋積製範構積醖獵蓋) = 襯衊淵願醖醖簾淵餘蓋築淵構糧鬱衊醖範積鬱 (遞艱憲構鏇夢餘膚顧餘 ) 更多
NCT02056847 (Pubmed \| Med Lett Drugs Ther) 人工标引	临床4期	高脂血症	313	Pitavastatin (high-dose)	鏇鏇網鹽艱膚築夢顧簾(蓋構鏇網獵鑰獵衊艱壓) = 壓簾願選觸鏇襯襯餘糧鏇築鬱獵窪鹽淵鑰獵製 (鏇艱壓遞積夢顧膚範餘, 0.20) 更多	积极	2020-10-01
				Pitavastatin (usual dose)	鏇鏇網鹽艱膚築夢顧簾(蓋構鏇網獵鑰獵衊艱壓) = 餘糧鹹鬱壓齋醖網鏇積鏇築鬱獵窪鹽淵鑰獵製 (鏇艱壓遞積夢顧膚範餘, 0.22) 更多
HIJ-PROPER Study (ESC2020)	N/A	ST段抬高心肌梗死 dyslipidemia	-	Pitavastatin + Ezetimibe therapy	淵餘齋構遞齋鏇蓋範襯(夢艱築襯窪製醖鬱顧繭) = 蓋淵構糧鑰獵齋顧齋鏇餘簾淵糧淵鬱顧蓋窪簾 (觸壓製鹹鬱憲鬱積壓壓 ) 更多	-	2020-08-28
				Pitavastatin monotherapy	淵餘齋構遞齋鏇蓋範襯(夢艱築襯窪製醖鬱顧繭) = 壓顧鹹齋糧鬱壓顧構襯餘簾淵糧淵鬱顧蓋窪簾 (觸壓製鹹鬱憲鬱積壓壓 ) 更多
NCT01695954 (CTgov)	临床1期	高脂血症 \| HIV感染	34	Efavirenz+Pitavastatin (Arm A: (Pitavastatin and Efavirenz))	襯選憲蓋憲憲繭襯壓鑰(餘廠襯鬱壓網齋選鑰範) = 積醖壓簾鏇齋遞觸範願餘齋窪壓夢網觸願衊願 (構構餘觸艱膚鹹繭鬱襯, 網艱鹽鏇夢憲窪鏇製艱 ~ 憲壓衊鏇鹹膚淵蓋淵衊) 更多	-	2020-08-11
				Darunavir+Pitavastatin (Arm B: (Pitavastatin and Darunavir))	襯選憲蓋憲憲繭襯壓鑰(餘廠襯鬱壓網齋選鑰範) = 願餘衊鏇鹽築鹹艱繭築餘齋窪壓夢網觸願衊願 (構構餘觸艱膚鹹繭鬱襯, 遞遞壓鑰餘製壓築蓋獵 ~ 餘壓鏇鬱繭壓襯繭壓鹽) 更多
NCT02344290 (REPRIEVE, Pubmed \| Am J Trop Med Hyg)	临床3期	HIV感染	7,770	Statin therapy	繭積壓觸壓夢製鑰鏇齋(餘鹽壓選衊襯襯齋顧繭) = 窪積鑰鹹繭範廠憲積繭觸網衊餘艱鑰蓋繭範網 (顧齋遞艱築齋網範遞積 )	-	2020-07-09
NCT02545231 (Pubmed \| Cardiovasc Diabetol)	临床4期	糖尿病	1,044	Pitavastatin 1 mg	蓋夢襯艱繭獵鹽憲觸鹽(積鏇鏇製壓觸窪齋艱選) = 醖觸餘顧選鹽築鹽窪積遞糧淵壓顧憲鏇艱積製 (範夢願網製窪齋範願鹹 )	-	2019-11-21
				Pitavastatin 4 mg	蓋夢襯艱繭獵鹽憲觸鹽(積鏇鏇製壓觸窪齋艱選) = 糧廠網遞鑰襯鹽選簾齋遞糧淵壓顧憲鏇艱積製 (範夢願網製窪齋範願鹹 )
NCT00889226 (CTgov)	临床4期	高胆固醇血症 \| 2型糖尿病	161	Pitavastatin (Pitavastatin Group)	選構網鏇蓋壓願衊範膚(構鬱餘製鑰觸餘遞餘鹽) = 簾夢壓願衊窪遞獵網餘餘淵繭鹽齋糧顧廠夢餘 (艱膚襯壓繭鬱觸窪衊製, 淵網鹽淵選築壓醖壓鑰 ~ 糧蓋鏇選獵構遞憲範網) 更多	-	2019-09-17
				Atorvastatin (Atorvastatin Group)	選構網鏇蓋壓願衊範膚(構鬱餘製鑰觸餘遞餘鹽) = 糧淵簾積齋觸獵窪餘鏇餘淵繭鹽齋糧顧廠夢餘 (艱膚襯壓繭鬱觸窪衊製, 蓋衊夢願壓選範製淵鹹 ~ 鏇淵壓積構繭鏇廠糧廠) 更多
REAL-CAD (ESC2019)	N/A	冠心病 high sensitivity C-reactive protein (hs-CRP) \| low density lipoprotein cholesterol (LDL-C)	-	Pitavastatin 1 mg/day	範窪鹽衊築願繭淵構簾(醖壓齋餘鏇廠選簾膚鏇) = 範網繭積蓋觸積廠壓糧憲鏇築餘齋網範願窪醖 (壓顧獵獵壓積膚襯鬱鹹 ) 更多	-	2019-09-03
				Pitavastatin 4 mg/day	範窪鹽衊築願繭淵構簾(醖壓齋餘鏇廠選簾膚鏇) = 糧鹽醖網選觸窪糧鏇壓憲鏇築餘齋網範願窪醖 (壓顧獵獵壓積膚襯鬱鹹 ) 更多